Open AccessEvaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [18F]DASA-23
Author(s) -
Corinne Beinat,
Chirag B. Patel,
Yuanyang Xie,
Sanjiv S. Gambhir
Publication year - 2019
Publication title -
molecular imaging and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.846
H-Index - 68
eISSN - 1860-2002
pISSN - 1536-1632
DOI - 10.1007/s11307-019-01353-2
Subject(s) - erlotinib , chemistry , pharmacology , pyruvate kinase , irinotecan , pkm2 , glioma , cancer research , glycolysis , medicine , epidermal growth factor receptor , cancer , metabolism , biochemistry , receptor , colorectal cancer
Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, the key process of tumor metabolism. PKM2 is found in high levels in glioblastoma (GBM) cells with marginal expression within healthy brain tissue, rendering it a key biomarker of GBM metabolic re-programming. Our group has reported the development of a novel radiotracer, 1-((2-fluoro- 6-[ 18 F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([ 18 F]DASA- 23), to non-invasively detect PKM2 levels with positron emission tomography (PET).